COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,585 Articles (22,905 medRxiv, 8,680 bioRxiv)

Most recent first Previous |  Page 354: Articles 3531-3540  | Next

Evaluation of the neutralising antibody response in human and hamster sera against SARS-CoV-2 variants up to and including BA.2.86 using an authentic virus neutralisation assay
Coombes, N. S., Bewley, K. R., Le Duff, Y., Alami-Rahmouni, N., Ryan, K. A., Kempster, S., Ferguson, D., Davies, E. R., Weldon, T. M., Cross, E. S., Smith, L., Norris, C., Rogers-Broadway, K. R., Lewandowski, K., Treagus, S., Pullan, S. T., Hallis, B., Charlton, S., Hall, Y., Funnell, S. G. P.
10.1101/2023.10.21.563398 — Posted: 2023-10-23
Viral envelope proteins fused to multiple distinct fluorescent reporters to probe receptor binding
Tomris, I., van der Woude, R., de Paiva Droes Rocha, R., Torrents de la Pena, A., Ward, A. B., de Vries, R. P.
10.1101/2023.10.23.563555 — Posted: 2023-10-23
Assessing nanobody interaction with SARS-CoV-2 Nsp9
Esposito, G., Hunashal, Y., Percipalle, M., Fogolari, F., Venit, T., Leonchiks, A., Gunsalus, K. C., Piano, F., Percipalle, P.
10.1101/2023.10.20.563308 — Posted: 2023-10-23
Changes in total charge on spike protein of SARS-CoV-2 in emerging lineages
Bozic, A., Podgornik, R.
10.1101/2023.10.21.563433 — Posted: 2023-10-23
Screening Peptide Drug Candidates to Neutralize Whole Viral Agents : A Case study with SARS-CoV-2 Virus
Ozcelik, C. E., Araz, C. Z., Yilmaz, O., Gulyuz, S., Ozkul, A., Seker, U. O. S.
10.1101/2023.10.22.563490 — Posted: 2023-10-23
A bioactive peptide from the pearl has dual roles in resisting SARS-CoV-2 infection and its complications
Liu, X., Wang, Y., Yin, Z., Wang, Q., Chen, X., Li, B., Yao, L., Zhang, Z., Zhang, R.
10.1101/2023.10.23.563427 — Posted: 2023-10-23
Perceptions and responses to COVID-19 through wastewater surveillance information and online search behavior: A randomized controlled trial
Murakami, M., Nomura, S., Ando, H., Kitajima, M.
10.1101/2023.10.20.23297297 — Posted: 2023-10-21
Factors Influencing the Trajectory of COVID-19 Evolution: A Longitudinal Study of 12 Asian Countries
He, X., Liu, H., Zeng, F., Gao, W.
10.1101/2023.10.20.23297319 — Posted: 2023-10-21
Dynamics of SARS-CoV-2 Seroprevalence in a Large US population Over a Period of 12 Months
Karkanitsa, M., Li, Y., Valenti, S., Spathies, J., Kelly, S., Yee, L., Croker, J. A., Wang, J., Lucia Alfonso, A., Faust, M., Mehalko, J., Drew, M., Denson, J.-P., Putman, Z., Fathi, P., Ngo, T. B., Siripong, N., Ann Baus, H., Petersen, B., Ford, E. W., Sundaresan, V., Sundaresan, V., Josyula, A., Han, A., Giurgea, L. T., Angela Rosas, L., Bean, R., Athota, R., Czajkowski, L., Klump-Thomas, C., Cervantes-Medina, A., Gouzoulis, M., Reed, S., Graubard, B., Hall, M. D., Kalish, H., Esposito, D., Kimberly, R. P., Reis, S., Sadtler, K., Memoli, M. J.
10.1101/2023.10.20.23297329 — Posted: 2023-10-21
Is Recovery Just the Beginning? Persistent Symptoms and Health and Performance Deterioration in Post-COVID-19, non-hospitalised University Students - A Cross-Sectional Study
Latifi, A., Flegr, J.
10.1101/2023.10.20.23297203 — Posted: 2023-10-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).